Literature DB >> 16485141

Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5.

Eric C K Siu1, Dieter B Wildenauer, Rachel F Tyndale.   

Abstract

RATIONALE: Cyp2a5, the mouse homologue of human CYP2A6, encodes for the enzyme responsible for the primary metabolism of nicotine. Variation in human CYP2A6 activity can alter the amount smoked such as number of cigarettes smoked per day and smoking intensity. Different mouse strains self-administer different amounts of oral nicotine and quantitative trait loci analyses in mice suggested that Cyp2a5 may be involved in differential nicotine consumption behaviors.
OBJECTIVES: The goal of this study was to examine whether in vivo nicotine consumption levels were associated with CYP2A5 protein levels and in vitro nicotine metabolism in mice.
METHODS: F2 mice propagated from high (C57Bl/6) and low (St/bJ) nicotine consuming mice were analyzed for CYP2A5 hepatic protein levels and in vitro nicotine metabolizing activity.
RESULTS: We found that F2 male high-nicotine (n=8; 25.1+/-1.2 microg nicotine/day) consumers had more CYP2A5 protein, compared to low (n=11; 3.8+/-1.4 microg nicotine/day) consumers (10.2+/-1.0 vs 6.5+/-1.3 CYP2A5 units). High consumers also metabolized nicotine faster than the low consumers (6 microM: 0.18+/-0.04 vs 0.14+/-0.07; 30 microM: 0.36+/- 0.06 vs 0.26+/-0.13; 60 microM: 0.49+/-0.05 vs 0.32+/-0.17 nmol/min/mg). In contrast, female high- (25.1+/-2.1 microg nicotine/day) and low-nicotine (4.7+/-1.4 microg nicotine/day) consumers did not show pronounced differences in nicotine metabolism or CYP2A4/5 protein levels; this is consistent with other studies of sex differences in response to nicotine.
CONCLUSIONS: These data suggested that among male F2 mice, increased nicotine self-administration is associated with increased rates of nicotine metabolism, most likely, as a result of greater CYP2A5 protein levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485141     DOI: 10.1007/s00213-006-0306-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  40 in total

1.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.

Authors:  Y Rao; E Hoffmann; M Zia; L Bodin; M Zeman; E M Sellers; R F Tyndale
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

Review 2.  Decreasing smoking behaviour and risk through CYP2A6 inhibition.

Authors:  Edward M Sellers; Rachel F Tyndale; Leona C Fernandes
Journal:  Drug Discov Today       Date:  2003-06-01       Impact factor: 7.851

3.  Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.

Authors:  Kerri A Schoedel; Edward M Sellers; Roberta Palmour; Rachel F Tyndale
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

4.  Influence of tobacco abstinence on the disposition kinetics and effects of nicotine.

Authors:  B L Lee; N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

5.  Variation of nicotinic binding sites among inbred strains.

Authors:  M J Marks; E Romm; S M Campbell; A C Collins
Journal:  Pharmacol Biochem Behav       Date:  1989-07       Impact factor: 3.533

Review 6.  Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies.

Authors:  J N Crawley; J K Belknap; A Collins; J C Crabbe; W Frankel; N Henderson; R J Hitzemann; S C Maxson; L L Miner; A J Silva; J M Wehner; A Wynshaw-Boris; R Paylor
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

7.  Genetic influences on acute responses to nicotine and nicotine tolerance in the mouse.

Authors:  A C Collins; L L Miner; M J Marks
Journal:  Pharmacol Biochem Behav       Date:  1988-05       Impact factor: 3.533

8.  Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

Review 9.  The scientific case that nicotine is addictive.

Authors:  I P Stolerman; M J Jarvis
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

10.  Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).

Authors:  Kazuma Kiyotani; Hiroshi Yamazaki; Masaki Fujieda; Shunsuke Iwano; Keiko Matsumura; Soisungwan Satarug; Pailin Ujjin; Tsutomu Shimada; F Peter Guengerich; Andrew Parkinson; Goro Honda; Kazuko Nakagawa; Takashi Ishizaki; Tetsuya Kamataki
Journal:  Pharmacogenetics       Date:  2003-11
View more
  35 in total

1.  The β3 subunit of the nicotinic acetylcholine receptor: Modulation of gene expression and nicotine consumption.

Authors:  Helen M Kamens; Jill Miyamoto; Matthew S Powers; Kasey Ro; Marissa Soto; Ryan Cox; Jerry A Stitzel; Marissa A Ehringer
Journal:  Neuropharmacology       Date:  2015-08-25       Impact factor: 5.250

2.  Flavor-specific enhancement of electronic cigarette liquid consumption and preference in mice.

Authors:  A L Wong; S M McElroy; J M Robinson; S M Mulloy; F K El Banna; A C Harris; M G LeSage; A M Lee
Journal:  Drug Alcohol Depend       Date:  2020-04-25       Impact factor: 4.492

3.  A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.

Authors:  Man Ki Ho; Jill C Mwenifumbo; Bin Zhao; Elizabeth M J Gillam; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

4.  Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.

Authors:  Deniz Bagdas; Pretal P Muldoon; Andy Z X Zhu; Rachel F Tyndale; M Imad Damaj
Journal:  Neuropharmacology       Date:  2014-05-21       Impact factor: 5.250

5.  Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Authors:  Timothy W Lefever; Youn O K Lee; Alexander L Kovach; Melanie A R Silinski; Julie A Marusich; Brian F Thomas; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2017-01-18       Impact factor: 4.492

6.  Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine.

Authors:  Douglas M McMillan; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2015-01-29       Impact factor: 7.853

7.  First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo.

Authors:  Kaidi Zhou; Jibran Y Khokhar; Bin Zhao; Rachel F Tyndale
Journal:  Biochem Pharmacol       Date:  2013-04-23       Impact factor: 5.858

8.  Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse.

Authors:  Lei Li; Kunzhi Jia; Xin Zhou; Sarah E McCallum; Lindsay B Hough; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2013-09-17       Impact factor: 4.030

9.  Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.

Authors:  Megan J Shram; Eric C K Siu; Zhaoxia Li; Rachel F Tyndale; Anh D Lê
Journal:  Psychopharmacology (Berl)       Date:  2008-04-03       Impact factor: 4.530

Review 10.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.